Cytokinetics (NASDAQ:CYTK) Stock Rating Lowered by Wall Street Zen

Cytokinetics (NASDAQ:CYTK) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Wall Street Zen reports.

CYTK has been the subject of several other reports. Barclays lifted their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Citizens Jmp increased their target price on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Royal Bank Of Canada increased their target price on Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Mizuho raised their price target on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. Finally, Needham & Company LLC raised their price target on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics has an average rating of “Moderate Buy” and a consensus target price of $105.44.

Cytokinetics Stock Down 1.7%

Shares of NASDAQ:CYTK opened at $62.86 on Tuesday. Cytokinetics has a fifty-two week low of $54.30 and a fifty-two week high of $88.31. The firm’s 50 day moving average price is $69.38 and its 200 day moving average price is $73.21. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of -8.71 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. During the same quarter last year, the firm earned ($1.12) EPS. The company’s revenue was down 57.1% on a year-over-year basis. On average, equities analysts anticipate that Cytokinetics will post -5.97 EPS for the current year.

Insider Buying and Selling

In related news, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the transaction, the director owned 10,784 shares in the company, valued at $770,840.32. This trade represents a 31.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the transaction, the executive vice president directly owned 58,555 shares in the company, valued at approximately $4,677,373.40. This trade represents a 19.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,426 shares of company stock worth $13,543,855 in the last quarter. 2.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in Cytokinetics by 11.9% during the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company’s stock worth $72,072,000 after purchasing an additional 116,593 shares during the period. ADAR1 Capital Management LLC increased its stake in Cytokinetics by 17.1% in the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company’s stock valued at $41,692,000 after purchasing an additional 92,390 shares during the period. Siren L.L.C. acquired a new position in Cytokinetics in the first quarter valued at $40,466,000. Handelsbanken Fonder AB increased its stake in Cytokinetics by 63.8% in the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 157,700 shares during the period. Finally, E. Ohman J or Asset Management AB raised its holdings in shares of Cytokinetics by 1.3% in the second quarter. E. Ohman J or Asset Management AB now owns 304,611 shares of the biopharmaceutical company’s stock valued at $25,950,000 after buying an additional 3,849 shares during the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Cytokinetics, providing continued analyst support for the company’s pipeline and commercial prospects. HC Wainwright rating report
• Positive Sentiment: Cytokinetics scheduled its third-quarter results for November 4, 2026, followed by a management conference call. The report will provide an important update on financial performance, aficamten commercialization and the company’s outlook. Cytokinetics third-quarter results announcement
• Neutral Sentiment: The company granted inducement awards covering 60,465 shares through stock options and 40,084 restricted stock units to 29 new employees. The grants support hiring but could modestly dilute existing shareholders over time. Cytokinetics inducement grants announcement
• Negative Sentiment: BofA Securities reduced its price target to $81 from $85 while maintaining a Neutral rating, signaling more limited near-term conviction even though the target remains above recent trading levels. BofA Securities price-target update
• Negative Sentiment: Wall Street Zen lowered Cytokinetics to a Sell rating, adding to concerns about valuation, execution and the company’s continuing losses. Wall Street Zen downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares for approximately $224,000. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, its bearish signaling value is limited, but it adds to the recent pattern of insider sales. SEC insider transaction filing

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.